Julius Knowles, Director at Keros Therapeutics, Inc. (KROS), bought 1,191 shares at $20.98 ($25K) on 2020-04-13, disclosed to the SEC on 2023-01-20.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| Filing → |
| KROS | SELL | 2021-12-03 | $5.1M | — | Filing → |
| KROS | SELL | 2021-11-03 | $3.9M | — | Filing → |
| KROS | SELL | 2021-10-21 | $598K | — | Filing → |